×
About 3,670 results

ALLMedicine™ Neurofibromatosis Type 1 Center

Research & Reviews  1,388 results

Gastrointestinal Stromal Tumors and their Appearance in Patients with Neurofibromatosis...
https://doi.org/10.1148/rg.220062
Radiographics : a Review Publication of the Radiological ... Murphy AN, Kearns C

May 21st, 2022 - Gastrointestinal Stromal Tumors and their Appearance in Patients with Neurofibromatosis Type 1.|2022|Murphy AN,Kearns C,|

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
https://clinicaltrials.gov/ct2/show/NCT02407405

May 20th, 2022 - Background: Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with an incidence of 1:3500 in the US. One of the cardinal features of NF1 is the development of histologically benign peripheral nervesheath tumors called plexiform neurofibr...

Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress
https://clinicaltrials.gov/ct2/show/NCT02423031

May 20th, 2022 - Objective: The purpose of this study is to develop and implement Checking In, a brief and interactive screening measure of distress, designed to identify emotional, physical, social, practical and spiritual concerns of pediatric patients. An accom...

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)
https://clinicaltrials.gov/ct2/show/NCT01702922

May 20th, 2022 - Background: Parents face numerous stressors when their child is diagnosed with cancer or NF1, each of which can strain a marriage/partnership. Marital/partner relationship dynamics are often not assessed or addressed when providing health care for...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 20th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

see more →

Guidelines  4 results

Care of adults with neurofibromatosis type 1: a clinical practice resource of the Ameri...
https://doi.org/10.1038/gim.2018.28
Genetics in Medicine : Official Journal of the American C... Stewart DR, Korf BR et. al.

Jul 15th, 2018 - This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessaril...

Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the d...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578356
Neurology Walsh KS, Janusz J et. al.

Aug 17th, 2016 - Neurofibromatosis type 1 (NF1) is associated with neurocognitive deficits that can impact everyday functioning of children, adolescents, and adults with this disease. However, there is little agreement regarding measures to use as cognitive endpoi...

Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578358
Neurology Plotkin SR, Davis SD et. al.

Aug 17th, 2016 - Plexiform neurofibromas (PNs) are complex, benign nerve sheath tumors that occur in approximately 25%-50% of individuals with neurofibromatosis type 1 (NF1). PNs that cause airway compromise or pulmonary dysfunction are uncommon but clinically imp...

Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578359
Neurology Ahlawat S, Fayad LM et. al.

Aug 17th, 2016 - The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with ne...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  35 results

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
https://clinicaltrials.gov/ct2/show/NCT02407405

May 20th, 2022 - Background: Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with an incidence of 1:3500 in the US. One of the cardinal features of NF1 is the development of histologically benign peripheral nervesheath tumors called plexiform neurofibr...

Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress
https://clinicaltrials.gov/ct2/show/NCT02423031

May 20th, 2022 - Objective: The purpose of this study is to develop and implement Checking In, a brief and interactive screening measure of distress, designed to identify emotional, physical, social, practical and spiritual concerns of pediatric patients. An accom...

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)
https://clinicaltrials.gov/ct2/show/NCT01702922

May 20th, 2022 - Background: Parents face numerous stressors when their child is diagnosed with cancer or NF1, each of which can strain a marriage/partnership. Marital/partner relationship dynamics are often not assessed or addressed when providing health care for...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 20th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
https://clinicaltrials.gov/ct2/show/NCT03531814

May 20th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic disorder that affects approximately 1 in 3,500 individuals and is associated with a broad variety of symptoms and physical findings. Plexiform neurofibromas (PN) are histologically benign tum...

see more →

News  34 results

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST
https://www.onclive.com/view/dr-trent-on-the-utility-of-ctdna-to-understand-primary-mutations-in-gist

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the utility of circulating tumor DNA (ctDNA) to understand primary driver...

Novel Test Distinguishes Benign From Malignant Lesions in NF1
https://www.medscape.com/viewarticle/958224

Sep 6th, 2021 - A novel liquid biopsy test has been shown to distinguish between patients with neurofibromatosis type 1 (NF1) who have benign plexiform neurofibroma (PN) precursor lesions from patients who have malignant peripheral nerve sheath tumors (MPNST), sa...

Genetic testing for neurofibromatosis 1: An imperfect science
https://www.mdedge.com/dermatology/article/243441/pediatrics/genetic-testing-neurofibromatosis-1-imperfect-science
Doug Brunk

Jul 27th, 2021 - When a child presents with café au lait macules, when is genetic testing for neurofibromatosis type 1 (NF1) advised? According to Peter Kannu, MB, ChB, DCH, PhD, a definitive diagnosis of NF1 can be made in most children using National Institutes.

Neurofibromatosis 1: Making the Diagnosis, With and Without Genetic Testing
https://www.medscape.com/viewarticle/955499

Jul 27th, 2021 - When a child presents with café au lait macules, when is genetic testing for neurofibromatosis type 1 (NF1) advised? According to Peter Kannu, MB, ChB, DCH, PhD, a definitive diagnosis of NF1 can be made in most children using National Institutes ...

Selumetinib Approved in Europe for Pediatric Neurofibromatosis Type 1 and Plexiform Neurofibromas
https://www.onclive.com/view/selumetinib-approved-in-europe-for-pediatric-neurofibromatosis-type-1-and-plexiform-neurofibromas

Jun 22nd, 2021 - The European Commission has granted a conditional approval to selumetinib (Koselugo) for the treatment of pediatric patients with symptomatic, inoperable plexiform neurofibromas (PN) and neurofibromatosis type 1 (NF1) who are at least 3 years of a...

see more →

Patient Education  6 results see all →